Search
Spyre Therapeutics Inc
SYREAdd to Watchlist
104.525USD
+0.895+0.86%
Market hours （ET）Quotes delayed by 15 min
9.20BMarket Cap
LossP/E TTM
Forecast
Currency: USD Updated: 2026-08-14The current earnings forecast score of Spyre Therapeutics Inc is 8.94, ranking 32 out of 387 in the Biotechnology & Medical Research industry. The average price target is 49.00, with a high of 70.00 and a low of 21.00.
Analyst Rating
Based on
17
analysts
Buy
Current Rating
124.714
Target Price
+20.35%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
497
Total
6
Median
7
Average
Company name
Ratings
Analysts
Spyre Therapeutics Inc
SYRE
17
argenx SE
ARGX
28
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
25
IQVIA Holdings Inc
IQV
24
Kymera Therapeutics Inc
KYMR
23
1
2
3
...
100
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Spyre Therapeutics Inc's price target?
Analysts forecast that Spyre Therapeutics Inc's price target is USD 49.00, with the highest forecast at USD 70.00 and the lowest forecast at USD 21.00.
How have Spyre Therapeutics IncSYRE's recent earnings per share performed?
The market expectation was USD -0.43, while Spyre Therapeutics IncSYRE's earnings per share (EPS) for the previous quarter was USD -0.88. EPS for the next quarter is expected at USD -0.75.
What is the analyst rating for Spyre Therapeutics Inc?
Based on the ratings of Spyre Therapeutics Inc's stock from 17 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.